Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users

Journal of Opioid Management

Volumn 8, Issue 5, 2012, Pages 315-327

  Schoedel, Kerri A ^a   Rolleri, Robert L ^b   Faulknor, Janice Y ^a   Pixton, Glenn C ^b   Chen, Nancy ^a   Bass, Almasa ^b   Sommerville, Kenneth W ^b   Sellers, Edward ^c,d,e  

^a SYNEOS HEALTH   (United States)

^b PFIZER INC   (United States)

^c Kendle Early Stage   (Canada)

^d DL Global Partners Inc   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Abuse potential; Drug liking; Intranasal; Misuse; Opioid; Oxycodone

Indexed keywords

OPIATE; OXYCODONE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG USE; FACE PAIN; FEMALE; HUMAN; LACRIMATION DISORDER; MALE; NASAL DISCOMFORT; NOSE OBSTRUCTION; PHARMACODYNAMICS; PULSE RATE; PUPILLOMETRY; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TABLET FORMULATION; THROAT IRRITATION; VISUAL ANALOG SCALE;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OXYCODONE; PUPIL; STREET DRUGS; TABLETS;

EID: 84870175227     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2012.0131     Document Type: Article

References (19)

1. Kuehn BM: Opioid prescriptions soar: Increase in legitimate use as well as abuse. JAMA. 2007; 297(3): 249-251.
2. Manchikanti L: National drug control policy and prescription drug abuse: Facts and fallacies. Pain Physician. 2007; 10(3): 399-424.
3. Birnbaum HG, White AG, Reynolds JL, et al.: Estimated costs of prescription opioid analgesic abuse in the United States in 2001: A societal perspective. Clin J Pain. 2006; 22(8): 667-676.
4. US Department of Health and Human Services, Centers for Disease Control and Prevention: Emergency department visits involving nonmedical use of selected prescription drugs-United States, 2004-2008. MMWR Morb Mortal Wkly Rep. 2010; 59(23): 705-714.
5. Warner M, Chen LH, Makuc DM: Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. In National Center for Health Statistics (NCHS) Data Brief. Hyattsville, MD: National Center for Health Statistics, 2009.
6. Dart R: RADARS System Report: RADARS System Analysis of Data on Immediate Release Opioids Vs. Long Acting Opioids for King Pharmaceuticals, 2010.
7. Mccabe SE, Cranford JA, Boyd CJ, et al.: Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav. 2007; 32(3): 562-575.
8. Butler SF, Fernandez KC, Chang A, et al.: Measuring attractiveness for abuse of prescription opioids. Pain Med. 2010; 11(1): 67-80.
9. Hays L, Kirsh KL, Passik SD: Seeking drug treatment for oxycontin abuse: A chart review of consecutive admissions to a substance abuse treatment facility in Kentucky. J Natl Compr Canc Netw. 2003; 1(3): 423-428.
10. Young AM, Havens JR, Leukefeld CG: Route of administration for illicit prescription opioids: A comparison of rural and urban drug users. Harm Reduct J. 2010; 7: 24.
11. Butler SF, Budman SH, Licari A, et al.: National addictions vigilance intervention and prevention program (NAVIPPROTM): A real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacol Drug Saf. 2008; 17(12): 1142-1154.
12. Katz N, Dart RC, Bailey E, et al.: Tampering with prescription opioids: Nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011; 37(4): 205-217.
13. Oxecta [Package Insert]. Bristol, TN: Pfizer Inc, June 2011.
14. American Psychiatric Association: Substance-related disorders. In Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000: 191.
15. Wesson DR, Ling W: The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003; 35(2): 253-259.
16. Roxicodone [Package Insert]. Newport, KY: Xanodyne Pharmaceuticals, Inc., 2009.
17. US Department of Health and Human Services, Food and Drug Administration: Guidance for Industry Assessment of Abuse Potential of Drugs. Silver Spring, MD: Center for Drug Evaluation and Research, 2010. Available at http://www.Fda.Gov/Downloads/Drugs/Guidancecomplianceregulatoryinformation/ Guidances/UCM198650.Pdf. Accessed August 28, 2012.
18. Griffiths RR, Bigelow GE, Ator NA: Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 2003; 70(3 Suppl): S41-S54.
19. Shram MJ, Schoedel KA, Setnik B, et al.: The relationship between objective and subjective effects measures used in abuse liability testing: An exploratory analysis using opioid agonists. Poster Presented at 73rd Annual Meeting of the College on Problems of Drug Dependence, Hollywood, FL, June 18-23, 2011.